Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recursion Pharmaceuticals, Inc.

https://recursionpharma.com/

Latest From Recursion Pharmaceuticals, Inc.

STING Agonist to SOS1 Inhibitor, Lupin Lines Up Oncology Pipeline

From a STING agonist to a SOS1 inhibitor, Lupin listed oncology candidates from the preclinical stage to those in IND-enabling studies during the recently concluded J.P. Morgan conference. Meanwhile, the newly spun-off oncology subsidiary awaits partners.

Research & Development Cancer

In Vivo’s Deals Of The Year 2021: Cast Your Vote!

It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

Deals M & A

IPO Outlook: 2021 Saw Record Numbers But Poor Returns; 2022 Looks Muted

Initial public offering momentum decelerated as stock prices declined last year, but even with lower valuations making M&A more attractive, the IPO market this year is expected to be active. 

Financing Scrip Perspectives

Amgen Joins AI/ML Gold Rush With Generate Deal

Deal Snapshot: At a same-day conference, Amgen’s CEO outlined the importance of AI/ML to the company’s drug development strategy, as numerous large biopharma companies have recently made similar deals.

Artificial Intelligence Deals
See All

Company Information

  • Industry
  • Digital Health
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • Other Names / Subsidiaries
    • Recursion Pharmaceuticals, LLC
UsernamePublicRestriction

Register